Table 1.
Patient characteristics (n = 17).
| Mean age, years ± standard deviation | 64 ± 8.2 |
| Male sex, n (%) | 13 (76.5) |
| Type of cancer, n (%) | |
| Melanoma | 8 (47.1) |
| Non-small-cell lung carcinoma | 4 (23.5) |
| Hepatocellular carcinoma | 2 (11.8) |
| Renal carcinoma | 2 (11.8) |
| Cutaneous T-cell lymphoma | 1 (5.9) |
| Type of ICI, n (%) | |
| Anti-PD1 | 16 (94.1) |
| Nivolumab | 6 (35.3) a |
| Pembrolizumab | 9 (52.9) a |
| Tislelizumab | 1 (5.9) a |
| Anti-PDL1 | 1 (5.9) |
| Atezolizumab | 1 (5.9) a |
| Associated treatment, n (%) | |
| Anti-VEGF antibody | 2 (11.8) |
| Axitinib | 1 (5.9) |
| Epacadostat | 1 (5.9) |
| Brentuximab vedodin | 1 (5.9) |
| History of autoimmune disease, n (%) | 0 (0) |
| History of other IRAEs, n (%) | 5 (29.4) |
| Thyroid dysfunction | 3 (17.6) |
| Vitiligo | 1 (5.9) |
ICI: immune checkpoint inhibitors, PD1: programmed cell death 1 protein, PDL1: programmed cell death 1 ligand 1, VEGF: vascular endothelial growth factor, IRAEs: immune related adverse events.a percent among all ICI.